In a message dated 6/29/02 3:47:32 PM, writes: << Also maybe we could speak to the Pharmaceutical rep from Bayer but do you think they will care unless we could prove statistically that Reyes Syndrome is on the rise? >> I think it's a waste of time to discuss it with a sales rep since they have no skin in that game and probably have little influence on issues like product labeling. As for Reyes Syndrome, nothing remains to be proven there. Probably the best way to influence the public is to put the information in the mass media: people learn everything they know from TV, so a commercial or news feature would probably reach most people. I could see Mike Wallace or some other 60 Minutes reporter asking Bayer people point blank why they continue to call the product Baby Aspirin. The only reason, of course, is name recognition and the profit motive. The Reyes Syndrome thing with all its attendant publicity happened when I first started practicing, about 20 years ago, when most of today's parents were little children themselves, so it's not surprising people don't know anymore why APAP is preferred to aspirin. Since the two drugs are synonymous to most people, and generally most people are not well informed about much of anything (since there is far too much information for anyone to assimilate and retain nowadays!), and the product is labeled as a pediatric product, it seems understandable that people are giving it to babies. On the other hand, since it's a labeling issue, and pertains to misleading labeling, and the FDA usually seems to handle those issues, it seems like something the AAP could address at that level. Stephanie Walker, RN, FNP